ロード中...
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
B-RAF is the most frequently mutated protein kinase in human cancers.1 The finding that oncogenic mutations in BRAF are common in melanoma2 followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway3 offered hope that inhibition of B-RAF kinase activity could benefit me...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2010
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2948082/ https://ncbi.nlm.nih.gov/pubmed/20823850 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature09454 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|